[HTML][HTML] Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment
D Zhao, J Chen, X Long, J Wang - Oncology Reports, 2021 - spandidos-publications.com
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non‑small cell lung cancer. These novel treatments exhibit improved efficacy …
treatment of non‑small cell lung cancer. These novel treatments exhibit improved efficacy …
Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment
D Zhao, J Chen, X Long, J Wang - Oncology Reports, 2020 - europepmc.org
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
Dose adjustment for tyrosine kinase inhibitors in non-small cell lung cancer patients with hepatic or renal function impairment
D Zhao, J Chen, X Long, J Wang - Oncology Reports, 2021 - go.gale.com
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
Dose adjustment for tyrosine kinase inhibitors in non-small cell lung cancer patients with hepatic or renal function impairment
D Zhao, J Chen, X Long, J Wang - Oncology Reports, 2021 - search.proquest.com
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment
D Zhao, J Chen, X Long, J Wang - Oncology reports, 2021 - pubmed.ncbi.nlm.nih.gov
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non‑small cell lung cancer. These novel treatments exhibit improved efficacy …
treatment of non‑small cell lung cancer. These novel treatments exhibit improved efficacy …
[PDF][PDF] Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment
D ZHAO, J CHEN, X LONG… - ONCOLOGY …, 2021 - pdfs.semanticscholar.org
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
[HTML][HTML] Dose adjustment for tyrosine kinase inhibitors in non-small cell lung cancer patients with hepatic or renal function impairment
D Zhao, J Chen, X Long, J Wang - Oncology Reports, 2021 - ncbi.nlm.nih.gov
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
treatment of non-small cell lung cancer. These novel treatments exhibit improved efficacy …
Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment
D ZHAO, J CHEN, X LONG, J WANG - ONCOLOGY REPORTS, 2021 - ingentaconnect.com
In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of nonsmall cell lung cancer. These novel treatments exhibit improved efficacy and …
treatment of nonsmall cell lung cancer. These novel treatments exhibit improved efficacy and …